Faknostics LLC
Phoenix, AZ
Company facts
- Self-certified in SAM.gov
- Entity structure
- Partnership or Limited Liability Partnership
- SAM.gov registration date
- Physical address
- 850 N 5th St #545, Phoenix, AZ 85004, USA
- Website
- faknostics.com
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Fibrobiologics LLC | Charleston, SC | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Fibronox, L.L.C. | Alpharetta, GA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Business | Del Mar, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Fibrotherapeutics Inc. | Charleston, SC | — |
| Covenant Therapeutics LLC | Charlottesville, VA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Faknostics LLC is a woman-owned small business registered in SAM.gov since September 2018, specializing in biomedical research and development with a focused approach on developing novel peptide-based inhibitors targeting specific protein interactions in fibrotic disease conditions. The Phoenix, Arizona-based limited liability partnership operates primarily in the biotechnology and pharmaceutical research sector, focusing on developing innovative therapeutic approaches for complex medical challenges.
The company has been awarded multiple federal grants from prominent health research agencies, specifically the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Heart Lung and Blood Institute (NHLBI). Their primary research efforts concentrate on developing non-catalytic FAK (Focal Adhesion Kinase) inhibitors as potential treatments for fibrotic conditions, including liver fibrosis and idiopathic pulmonary fibrosis (IPF). Recent grant awards, such as R42DK141379 and R42HL162392, support their research into developing stapled peptide-based inhibitors that target specific protein domain interactions. These grants, totaling approximately $651,952, demonstrate Faknostics' commitment to advancing therapeutic interventions for chronic diseases by exploring innovative molecular approaches that could potentially modify disease progression in conditions like liver fibrosis and lung fibrosis where current treatment options are limited.
SBA capabilities narrative
A comprehensive cancer diagnostics and therapeutics company based on a critical protein for cancer development and survival, Focal Adhesion Kinase (FAK).
Quick answers
Is Faknostics LLC registered in SAM.gov?
Yes. Faknostics LLC's SAM.gov registration is active through August 18, 2027.
What is Faknostics LLC's CAGE code?
Faknostics LLC's CAGE code is 85VE1, and its Unique Entity ID (UEI) is TK5AKDP8CSZ7.
What is Faknostics LLC's most recent federal award?
Faknostics LLC's most recent federal grant award is Novel paxillin-FAK inhibitors for the treatment of liver fibrosis (R42DK141379), from National Institute of Diabetes and Digestive and Kidney Diseases (NIH), on September 15, 2024.
On GovTribe
See Faknostics LLC's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors